Novo Nordisk to advance SC and oral amycretin development

Novo Nordisk (NOV: N) late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in weight management based on completed clinical studies and feedback received from regulatory authorities.

The decision to advance subcutaneous and oral amycretin into Phase III is based on feedback received from regulatory authorities following end-of-Phase II interactions for subcutaneous and oral amycretin in weight management, the Danish diabetes and obesity giant noted.

“We are very pleased that the feedback from regulatory authorities has allowed us to take subcutaneous and oral amycretin in weight management to Phase III,” said Martin Lange, executive vice president for development at Novo Nordisk, adding: “We are excited about the amycretin molecule, and this marks an important step forward. We look forward to sharing more information on the design of the Phase III program.”